NASDAQ:CSIICardiovascular Systems Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Cardiovascular Systems Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $32.25 +0.29 (+0.91 %) (As of 08/13/2020 01:20 PM ET) Add Compare Share Today's Range$31.76Now: $32.25▼$32.3050-Day Range$27.86MA: $31.04▼$34.4552-Week Range$26.00Now: $32.25▼$55.22Volume3,493 shsAverage Volume335,370 shsMarket Capitalization$1.14 billionP/E RatioN/ADividend YieldN/ABeta1.41 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Cardiovascular Systems, Inc., a medical device company, develops, manufactures, and commercializes various devices to treat vascular and coronary diseases in the United States. The company offers peripheral arterial disease products, including Diamondback 360 Peripheral, Predator 360, Stealth 360 Peripheral Orbital Atherectomy System (OAS), Diamondback 360 60cm Peripheral OAS, Diamondback 360 Low Profile Peripheral, Diamondback 360 1.50 Peripheral, Diamondback 360 2.00 Peripheral, Diamondback 360 200cm Peripheral, and Diamondback 360 180cm Peripheral, which are catheter-based platforms for treating a range of plaque types in leg arteries above and below the knee, including calcified plaque, as well as address various limitations associated with surgical, catheter, and pharmacological treatment alternatives. It also provides Diamondback 360 Coronary OAS, an atherectomy device for the treatment of calcified coronary arteries. Cardiovascular Systems, Inc. was founded in 1989 and is headquartered in St. Paul, Minnesota.Read More Beat the Market (BTM) Rank™ 4.5 Analyst's Opinion Consensus RatingCardiovascular Systems has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $46.75, Cardiovascular Systems has a potential upside of 44.8% from its current price of $32.29.Amount of Analyst CoverageCardiovascular Systems has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.6 Community Rank Outperform VotesCardiovascular Systems has received 400 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCardiovascular Systems has received 368 “underperform” votes. (Add your “underperform” vote.)Community SentimentCardiovascular Systems has received 52.08% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Cardiovascular Systems and other stocks. Vote “Outperform” if you believe CSII will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CSII will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCardiovascular Systems does not currently pay a dividend.Dividend GrowthCardiovascular Systems does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cardiovascular Systems insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.00% of the stock of Cardiovascular Systems is held by insiders.Percentage Held by Institutions92.67% of the stock of Cardiovascular Systems is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cardiovascular Systems are expected to grow in the coming year, from ($0.42) to ($0.08) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cardiovascular Systems is -41.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cardiovascular Systems is -41.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCardiovascular Systems has a P/B Ratio of 4.24. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 4.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.75 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment SectorMedical Current SymbolNASDAQ:CSII Previous Symbol CUSIP14161910 CIK1180145 Webwww.csi360.com Phone651-259-1600Debt Debt-to-Equity Ratio0.08 Current Ratio6.46 Quick Ratio5.84Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$236.54 million Price / Sales4.81 Cash FlowN/A Price / Cash FlowN/A Book Value$7.62 per share Price / Book4.23Profitability EPS (Most Recent Fiscal Year)($0.79) Net Income$-27,240,000.00 Net Margins-11.51% Return on Equity-15.62% Return on Assets-10.89%Miscellaneous Employees652 Outstanding Shares35,274,000Market Cap$1.14 billion Next Earnings Date11/3/2020 (Estimated) OptionableOptionable $32.25 +0.29 (+0.91 %) (As of 08/13/2020 01:20 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive CSII News and Ratings via Email Sign-up to receive the latest news and ratings for CSII and its competitors with MarketBeat's FREE daily newsletter. Cardiovascular Systems (NASDAQ:CSII) Frequently Asked Questions How has Cardiovascular Systems' stock price been impacted by Coronavirus (COVID-19)? Cardiovascular Systems' stock was trading at $36.32 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CSII shares have decreased by 11.2% and is now trading at $32.24. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Cardiovascular Systems? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cardiovascular Systems in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Cardiovascular Systems. When is Cardiovascular Systems' next earnings date? Cardiovascular Systems is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020. View our earnings forecast for Cardiovascular Systems. How were Cardiovascular Systems' earnings last quarter? Cardiovascular Systems Inc (NASDAQ:CSII) issued its earnings results on Tuesday, August, 4th. The medical device company reported ($0.43) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.44) by $0.01. Cardiovascular Systems had a negative return on equity of 15.62% and a negative net margin of 11.51%. View Cardiovascular Systems' earnings history. What guidance has Cardiovascular Systems issued on next quarter's earnings? Cardiovascular Systems updated its first quarter 2021 After-Hours earnings guidance on Tuesday, August, 4th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $55-58 million, compared to the consensus revenue estimate of $50 million. What price target have analysts set for CSII? 8 brokers have issued 12-month target prices for Cardiovascular Systems' stock. Their forecasts range from $40.00 to $58.00. On average, they expect Cardiovascular Systems' stock price to reach $46.75 in the next year. This suggests a possible upside of 45.0% from the stock's current price. View analysts' price targets for Cardiovascular Systems. Has Cardiovascular Systems been receiving favorable news coverage? News articles about CSII stock have been trending extremely negative on Thursday, according to InfoTrie. The research group ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Cardiovascular Systems earned a news sentiment score of -4.1 on InfoTrie's scale. They also assigned news headlines about the medical device company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the next few days. View the latest news about Cardiovascular Systems. Are investors shorting Cardiovascular Systems? Cardiovascular Systems saw a decrease in short interest in May. As of May 15th, there was short interest totaling 1,280,000 shares, a decrease of 16.9% from the April 30th total of 1,540,000 shares. Based on an average daily trading volume, of 315,100 shares, the short-interest ratio is presently 4.1 days. Approximately 3.8% of the shares of the stock are sold short. View Cardiovascular Systems' Short Interest. Who are some of Cardiovascular Systems' key competitors? Some companies that are related to Cardiovascular Systems include Abbott Laboratories (ABT), Medtronic (MDT), Intuitive Surgical (ISRG), Becton Dickinson and (BDX), Stryker (SYK), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), DexCom (DXCM), IDEXX Laboratories (IDXX), ResMed (RMD), Teleflex (TFX), Hologic (HOLX), Varian Medical Systems (VAR) and Steris (STE). View all competitors. What other stocks do shareholders of Cardiovascular Systems own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cardiovascular Systems investors own include AbbVie (ABBV), Gilead Sciences (GILD), Paypal (PYPL), Xcel Energy (XEL), Advanced Micro Devices (AMD), Mcdonald's (MCD), Medtronic (MDT), Netflix (NFLX), NVIDIA (NVDA) and Pfizer (PFE). Who are Cardiovascular Systems' key executives? Cardiovascular Systems' management team includes the following people: Mr. Scott Raymond Ward M.S., MS, B.Sc., Chairman, Pres & CEO (Age 59)Mr. Jeffrey S. Points, Chief Financial Officer (Age 42)Ms. Rhonda J. Robb, Chief Operating Officer (Age 51)Mr. Alexander Rosenstein, Gen. Counsel & Corp. Sec. (Age 47)Ms. Laura J. Gillund, Chief Talent Officer (Age 58) What is Cardiovascular Systems' stock symbol? Cardiovascular Systems trades on the NASDAQ under the ticker symbol "CSII." Who are Cardiovascular Systems' major shareholders? Cardiovascular Systems' stock is owned by many different retail and institutional investors. Top institutional shareholders include Peregrine Capital Management LLC (1.43%), Bank of New York Mellon Corp (1.06%), Principal Financial Group Inc. (0.77%), Monashee Investment Management LLC (0.71%), Goldman Sachs Group Inc. (0.65%) and GW&K Investment Management LLC (0.51%). Company insiders that own Cardiovascular Systems stock include Alexander Rosenstein, Jeffrey S Points, Martha Goldberg Aronson, Sandra Sedo and Scott R Ward. View institutional ownership trends for Cardiovascular Systems. Which institutional investors are selling Cardiovascular Systems stock? CSII stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., GW&K Investment Management LLC, Assenagon Asset Management S.A., Falcon Point Capital LLC, Russell Investments Group Ltd., Prudential Financial Inc., Principal Financial Group Inc., and Trexquant Investment LP. Company insiders that have sold Cardiovascular Systems company stock in the last year include Alexander Rosenstein, and Sandra Sedo. View insider buying and selling activity for Cardiovascular Systems. Which institutional investors are buying Cardiovascular Systems stock? CSII stock was acquired by a variety of institutional investors in the last quarter, including Monashee Investment Management LLC, Peregrine Capital Management LLC, Cambiar Investors LLC, First Quadrant L P CA, Comerica Bank, Macquarie Group Ltd., Swiss National Bank, and Exchange Traded Concepts LLC. Company insiders that have bought Cardiovascular Systems stock in the last two years include Martha Goldberg Aronson, and Scott R Ward. View insider buying and selling activity for Cardiovascular Systems. How do I buy shares of Cardiovascular Systems? Shares of CSII can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Cardiovascular Systems' stock price today? One share of CSII stock can currently be purchased for approximately $32.24. How big of a company is Cardiovascular Systems? Cardiovascular Systems has a market capitalization of $1.14 billion and generates $236.54 million in revenue each year. The medical device company earns $-27,240,000.00 in net income (profit) each year or ($0.79) on an earnings per share basis. Cardiovascular Systems employs 652 workers across the globe. What is Cardiovascular Systems' official website? The official website for Cardiovascular Systems is www.csi360.com. How can I contact Cardiovascular Systems? Cardiovascular Systems' mailing address is 1225 OLD HWY 8 NW, ST. PAUL MN, 55112. The medical device company can be reached via phone at 651-259-1600 or via email at [email protected] This page was last updated on 8/13/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
